Product Code: ETC13156086 | Publication Date: Apr 2025 | Updated Date: Jul 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Shubham Padhi | No. of Pages: 190 | No. of Figures: 80 | No. of Tables: 40 |
According to 6Wresearch internal database and industry insights, the Global Primary Biliary Cholangitis Market was valued at USD 1.3 Billion in 2024 and is expected to reach USD 1.8 Billion by 2031, growing at a compound annual growth rate of 5.20% during the forecast period (2025-2031).
The Global Primary Biliary Cholangitis (PBC) Market is expected to witness steady growth due to increasing awareness about the disease, advancements in diagnostic techniques, and the development of novel treatment options. PBC is a chronic autoimmune liver disease characterized by progressive destruction of the bile ducts, leading to liver damage. The market is driven by the rising prevalence of PBC, particularly among women, and the growing elderly population. Key players in the market are focusing on research and development activities to introduce innovative therapies for PBC management, including targeted therapies and biologics. Additionally, collaborations between pharmaceutical companies and healthcare organizations are expected to further drive market growth by improving access to diagnosis and treatment options for patients worldwide.
The Global Primary Biliary Cholangitis (PBC) market is experiencing significant growth driven by increasing awareness, improved diagnostic techniques, and evolving treatment options. Key trends include a rising prevalence of PBC, particularly in aging populations, leading to a higher demand for therapeutic interventions. The development of novel drug therapies, such as obeticholic acid, has provided new treatment options for patients with PBC, further propelling market expansion. Additionally, strategic collaborations between pharmaceutical companies and research institutions are fostering innovation in the field, offering opportunities for market growth and advancement. With a focus on personalized medicine and precision therapies, the Global PBC market is poised for continued expansion and development in the coming years.
The Global Primary Biliary Cholangitis (PBC) Market faces several challenges, including limited awareness among healthcare professionals and patients, leading to underdiagnosis and undertreatment of the disease. Additionally, the high cost of treatment options for PBC, such as ursodeoxycholic acid (UDCA) and emerging therapies, poses a barrier to access for many patients. The lack of effective biomarkers for disease progression and response to treatment also complicates the management of PBC. Furthermore, the relatively small patient population and the need for long-term management create challenges for conducting clinical trials and developing new therapies. Overall, addressing these challenges is crucial to improving outcomes for PBC patients and advancing research in this field.
The Global Primary Biliary Cholangitis Market is primarily driven by the increasing prevalence of primary biliary cholangitis (PBC) globally, coupled with a growing awareness about the disease among healthcare professionals and patients. Additionally, advancements in diagnostic techniques and the development of novel treatment options are fueling market growth. The rising geriatric population, who are more susceptible to PBC, and the increasing healthcare expenditure in developing countries are also contributing to the expansion of the market. Furthermore, strategic initiatives undertaken by key market players such as collaborations, partnerships, and product launches are boosting market competitiveness and driving further growth in the Global Primary Biliary Cholangitis Market.
Government policies related to the Global Primary Biliary Cholangitis Market primarily focus on ensuring patient access to affordable treatment options, promoting research and development for innovative therapies, and regulating the approval and marketing of pharmaceutical products. Regulatory agencies such as the FDA in the United States and the EMA in Europe play a crucial role in assessing the safety and efficacy of new treatments for PBC. Government initiatives also aim to support rare disease research, streamline drug approval processes, and provide incentives for pharmaceutical companies to invest in developing therapies for PBC. Additionally, healthcare policies strive to improve patient outcomes through increased awareness, early diagnosis, and timely access to specialized care for individuals living with PBC.
The Global Primary Biliary Cholangitis (PBC) Market is expected to witness steady growth in the coming years, driven by increasing awareness about the disease, advancements in diagnostic techniques, and the introduction of innovative treatment options. The market is likely to benefit from a growing patient population, particularly in developed countries with aging populations. Additionally, ongoing research and development efforts aimed at identifying new therapeutic targets and improving existing treatments are anticipated to further drive market growth. However, challenges such as high treatment costs and limited access to healthcare in certain regions may hinder market expansion. Overall, the Global PBC Market is poised for growth, with opportunities for pharmaceutical companies to develop novel therapies and improve patient outcomes.
In the Global Primary Biliary Cholangitis (PBC) market, Asia is expected to witness significant growth due to the rising prevalence of liver diseases in countries like China and India. North America holds a dominant position in the market due to advanced healthcare infrastructure and high awareness about PBC among the population. Europe is also a key market for PBC treatment, with countries like the UK, Germany, and France leading in research and development activities. The Middle East and Africa region is anticipated to show steady growth in the PBC market, driven by improving healthcare facilities and increasing investment in healthcare infrastructure. Latin America is also emerging as a promising market for PBC treatment, supported by growing healthcare expenditure and rising awareness about liver diseases in countries like Brazil and Mexico.
Global Primary Biliary Cholangitis Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Global Primary Biliary Cholangitis Market Overview |
3.1 Global Regional Macro Economic Indicators |
3.2 Global Primary Biliary Cholangitis Market Revenues & Volume, 2021 & 2031F |
3.3 Global Primary Biliary Cholangitis Market - Industry Life Cycle |
3.4 Global Primary Biliary Cholangitis Market - Porter's Five Forces |
3.5 Global Primary Biliary Cholangitis Market Revenues & Volume Share, By Regions, 2021 & 2031F |
3.6 Global Primary Biliary Cholangitis Market Revenues & Volume Share, By Treatment Type, 2021 & 2031F |
3.7 Global Primary Biliary Cholangitis Market Revenues & Volume Share, By Diagnosis, 2021 & 2031F |
3.8 Global Primary Biliary Cholangitis Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.9 Global Primary Biliary Cholangitis Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
3.10 Global Primary Biliary Cholangitis Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Global Primary Biliary Cholangitis Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Global Primary Biliary Cholangitis Market Trends |
6 Global Primary Biliary Cholangitis Market, 2021 - 2031 |
6.1 Global Primary Biliary Cholangitis Market, Revenues & Volume, By Treatment Type, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 Global Primary Biliary Cholangitis Market, Revenues & Volume, By Liver Transplantation, 2021 - 2031 |
6.1.3 Global Primary Biliary Cholangitis Market, Revenues & Volume, By Drug Therapy, 2021 - 2031 |
6.1.4 Global Primary Biliary Cholangitis Market, Revenues & Volume, By Ursodeoxycholic acid (UDCA), 2021 - 2031 |
6.1.5 Global Primary Biliary Cholangitis Market, Revenues & Volume, By Obeticholic acid, 2021 - 2031 |
6.1.6 Global Primary Biliary Cholangitis Market, Revenues & Volume, By Fibrates, 2021 - 2031 |
6.1.7 Global Primary Biliary Cholangitis Market, Revenues & Volume, By Budesonide, 2021 - 2031 |
6.1.8 Global Primary Biliary Cholangitis Market, Revenues & Volume, By Others, 2021 - 2031 |
6.2 Global Primary Biliary Cholangitis Market, Revenues & Volume, By Diagnosis, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 Global Primary Biliary Cholangitis Market, Revenues & Volume, By FibroScan, 2021 - 2031 |
6.2.3 Global Primary Biliary Cholangitis Market, Revenues & Volume, By Blood Tests, 2021 - 2031 |
6.2.4 Global Primary Biliary Cholangitis Market, Revenues & Volume, By Cholesterol Test, 2021 - 2031 |
6.2.5 Global Primary Biliary Cholangitis Market, Revenues & Volume, By Antibody Test, 2021 - 2031 |
6.2.6 Global Primary Biliary Cholangitis Market, Revenues & Volume, By Liver Test, 2021 - 2031 |
6.2.7 Global Primary Biliary Cholangitis Market, Revenues & Volume, By Others, 2021 - 2031 |
6.3 Global Primary Biliary Cholangitis Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
6.3.1 Overview & Analysis |
6.3.2 Global Primary Biliary Cholangitis Market, Revenues & Volume, By Oral, 2021 - 2031 |
6.3.3 Global Primary Biliary Cholangitis Market, Revenues & Volume, By Parenteral, 2021 - 2031 |
6.3.4 Global Primary Biliary Cholangitis Market, Revenues & Volume, By Others, 2021 - 2031 |
6.4 Global Primary Biliary Cholangitis Market, Revenues & Volume, By End-Users, 2021 - 2031 |
6.4.1 Overview & Analysis |
6.4.2 Global Primary Biliary Cholangitis Market, Revenues & Volume, By Hospitals, 2021 - 2031 |
6.4.3 Global Primary Biliary Cholangitis Market, Revenues & Volume, By Specialty Clinics, 2021 - 2031 |
6.4.4 Global Primary Biliary Cholangitis Market, Revenues & Volume, By Homecare, 2021 - 2031 |
6.4.5 Global Primary Biliary Cholangitis Market, Revenues & Volume, By Others, 2021 - 2031 |
6.5 Global Primary Biliary Cholangitis Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
6.5.1 Overview & Analysis |
6.5.2 Global Primary Biliary Cholangitis Market, Revenues & Volume, By Hospital Pharmacy, 2021 - 2031 |
6.5.3 Global Primary Biliary Cholangitis Market, Revenues & Volume, By Retail Pharmacy, 2021 - 2031 |
6.5.4 Global Primary Biliary Cholangitis Market, Revenues & Volume, By Online Pharmacy, 2021 - 2031 |
6.5.5 Global Primary Biliary Cholangitis Market, Revenues & Volume, By Others, 2021 - 2031 |
7 North America Primary Biliary Cholangitis Market, Overview & Analysis |
7.1 North America Primary Biliary Cholangitis Market Revenues & Volume, 2021 - 2031 |
7.2 North America Primary Biliary Cholangitis Market, Revenues & Volume, By Countries, 2021 - 2031 |
7.2.1 United States (US) Primary Biliary Cholangitis Market, Revenues & Volume, 2021 - 2031 |
7.2.2 Canada Primary Biliary Cholangitis Market, Revenues & Volume, 2021 - 2031 |
7.2.3 Rest of North America Primary Biliary Cholangitis Market, Revenues & Volume, 2021 - 2031 |
7.3 North America Primary Biliary Cholangitis Market, Revenues & Volume, By Treatment Type, 2021 - 2031 |
7.4 North America Primary Biliary Cholangitis Market, Revenues & Volume, By Diagnosis, 2021 - 2031 |
7.5 North America Primary Biliary Cholangitis Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
7.6 North America Primary Biliary Cholangitis Market, Revenues & Volume, By End-Users, 2021 - 2031 |
7.7 North America Primary Biliary Cholangitis Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
8 Latin America (LATAM) Primary Biliary Cholangitis Market, Overview & Analysis |
8.1 Latin America (LATAM) Primary Biliary Cholangitis Market Revenues & Volume, 2021 - 2031 |
8.2 Latin America (LATAM) Primary Biliary Cholangitis Market, Revenues & Volume, By Countries, 2021 - 2031 |
8.2.1 Brazil Primary Biliary Cholangitis Market, Revenues & Volume, 2021 - 2031 |
8.2.2 Mexico Primary Biliary Cholangitis Market, Revenues & Volume, 2021 - 2031 |
8.2.3 Argentina Primary Biliary Cholangitis Market, Revenues & Volume, 2021 - 2031 |
8.2.4 Rest of LATAM Primary Biliary Cholangitis Market, Revenues & Volume, 2021 - 2031 |
8.3 Latin America (LATAM) Primary Biliary Cholangitis Market, Revenues & Volume, By Treatment Type, 2021 - 2031 |
8.4 Latin America (LATAM) Primary Biliary Cholangitis Market, Revenues & Volume, By Diagnosis, 2021 - 2031 |
8.5 Latin America (LATAM) Primary Biliary Cholangitis Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
8.6 Latin America (LATAM) Primary Biliary Cholangitis Market, Revenues & Volume, By End-Users, 2021 - 2031 |
8.7 Latin America (LATAM) Primary Biliary Cholangitis Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
9 Asia Primary Biliary Cholangitis Market, Overview & Analysis |
9.1 Asia Primary Biliary Cholangitis Market Revenues & Volume, 2021 - 2031 |
9.2 Asia Primary Biliary Cholangitis Market, Revenues & Volume, By Countries, 2021 - 2031 |
9.2.1 India Primary Biliary Cholangitis Market, Revenues & Volume, 2021 - 2031 |
9.2.2 China Primary Biliary Cholangitis Market, Revenues & Volume, 2021 - 2031 |
9.2.3 Japan Primary Biliary Cholangitis Market, Revenues & Volume, 2021 - 2031 |
9.2.4 Rest of Asia Primary Biliary Cholangitis Market, Revenues & Volume, 2021 - 2031 |
9.3 Asia Primary Biliary Cholangitis Market, Revenues & Volume, By Treatment Type, 2021 - 2031 |
9.4 Asia Primary Biliary Cholangitis Market, Revenues & Volume, By Diagnosis, 2021 - 2031 |
9.5 Asia Primary Biliary Cholangitis Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
9.6 Asia Primary Biliary Cholangitis Market, Revenues & Volume, By End-Users, 2021 - 2031 |
9.7 Asia Primary Biliary Cholangitis Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
10 Africa Primary Biliary Cholangitis Market, Overview & Analysis |
10.1 Africa Primary Biliary Cholangitis Market Revenues & Volume, 2021 - 2031 |
10.2 Africa Primary Biliary Cholangitis Market, Revenues & Volume, By Countries, 2021 - 2031 |
10.2.1 South Africa Primary Biliary Cholangitis Market, Revenues & Volume, 2021 - 2031 |
10.2.2 Egypt Primary Biliary Cholangitis Market, Revenues & Volume, 2021 - 2031 |
10.2.3 Nigeria Primary Biliary Cholangitis Market, Revenues & Volume, 2021 - 2031 |
10.2.4 Rest of Africa Primary Biliary Cholangitis Market, Revenues & Volume, 2021 - 2031 |
10.3 Africa Primary Biliary Cholangitis Market, Revenues & Volume, By Treatment Type, 2021 - 2031 |
10.4 Africa Primary Biliary Cholangitis Market, Revenues & Volume, By Diagnosis, 2021 - 2031 |
10.5 Africa Primary Biliary Cholangitis Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
10.6 Africa Primary Biliary Cholangitis Market, Revenues & Volume, By End-Users, 2021 - 2031 |
10.7 Africa Primary Biliary Cholangitis Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
11 Europe Primary Biliary Cholangitis Market, Overview & Analysis |
11.1 Europe Primary Biliary Cholangitis Market Revenues & Volume, 2021 - 2031 |
11.2 Europe Primary Biliary Cholangitis Market, Revenues & Volume, By Countries, 2021 - 2031 |
11.2.1 United Kingdom Primary Biliary Cholangitis Market, Revenues & Volume, 2021 - 2031 |
11.2.2 Germany Primary Biliary Cholangitis Market, Revenues & Volume, 2021 - 2031 |
11.2.3 France Primary Biliary Cholangitis Market, Revenues & Volume, 2021 - 2031 |
11.2.4 Rest of Europe Primary Biliary Cholangitis Market, Revenues & Volume, 2021 - 2031 |
11.3 Europe Primary Biliary Cholangitis Market, Revenues & Volume, By Treatment Type, 2021 - 2031 |
11.4 Europe Primary Biliary Cholangitis Market, Revenues & Volume, By Diagnosis, 2021 - 2031 |
11.5 Europe Primary Biliary Cholangitis Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
11.6 Europe Primary Biliary Cholangitis Market, Revenues & Volume, By End-Users, 2021 - 2031 |
11.7 Europe Primary Biliary Cholangitis Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
12 Middle East Primary Biliary Cholangitis Market, Overview & Analysis |
12.1 Middle East Primary Biliary Cholangitis Market Revenues & Volume, 2021 - 2031 |
12.2 Middle East Primary Biliary Cholangitis Market, Revenues & Volume, By Countries, 2021 - 2031 |
12.2.1 Saudi Arabia Primary Biliary Cholangitis Market, Revenues & Volume, 2021 - 2031 |
12.2.2 UAE Primary Biliary Cholangitis Market, Revenues & Volume, 2021 - 2031 |
12.2.3 Turkey Primary Biliary Cholangitis Market, Revenues & Volume, 2021 - 2031 |
12.3 Middle East Primary Biliary Cholangitis Market, Revenues & Volume, By Treatment Type, 2021 - 2031 |
12.4 Middle East Primary Biliary Cholangitis Market, Revenues & Volume, By Diagnosis, 2021 - 2031 |
12.5 Middle East Primary Biliary Cholangitis Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
12.6 Middle East Primary Biliary Cholangitis Market, Revenues & Volume, By End-Users, 2021 - 2031 |
12.7 Middle East Primary Biliary Cholangitis Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
13 Global Primary Biliary Cholangitis Market Key Performance Indicators |
14 Global Primary Biliary Cholangitis Market - Export/Import By Countries Assessment |
15 Global Primary Biliary Cholangitis Market - Opportunity Assessment |
15.1 Global Primary Biliary Cholangitis Market Opportunity Assessment, By Countries, 2021 & 2031F |
15.2 Global Primary Biliary Cholangitis Market Opportunity Assessment, By Treatment Type, 2021 & 2031F |
15.3 Global Primary Biliary Cholangitis Market Opportunity Assessment, By Diagnosis, 2021 & 2031F |
15.4 Global Primary Biliary Cholangitis Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
15.5 Global Primary Biliary Cholangitis Market Opportunity Assessment, By End-Users, 2021 & 2031F |
15.6 Global Primary Biliary Cholangitis Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
16 Global Primary Biliary Cholangitis Market - Competitive Landscape |
16.1 Global Primary Biliary Cholangitis Market Revenue Share, By Companies, 2024 |
16.2 Global Primary Biliary Cholangitis Market Competitive Benchmarking, By Operating and Technical Parameters |
17 Top 10 Company Profiles |
18 Recommendations |
19 Disclaimer |